Stephen Hemsley, the board chair and former CEO of UnitedHealth Group, has sold ...
Only one company has responded to an FTC demand for several drugmakers to delist...
The Biden administration's assertion of its authority to exercise "march-in" rig...
LY-3885125 is under clinical development by Eli Lilly and Co and currently in Ph...
Tislelizumab is under clinical development by BeiGene and currently in Phase III...
IGM Biosciences plans to axe 22% of its workforce, becoming the latest company ...
Tislelizumab is under clinical development by BeiGene and currently in Pre-Regis...
Tislelizumab is under clinical development by BeiGene and currently in Phase III...
DB-1310 is under clinical development by Duality Biologics (Shanghai) and curren...
Sirolimus is under clinical development by OrphAI Therapeutics and currently in ...
Sirolimus is under clinical development by OrphAI Therapeutics and currently in ...
DB-1310 is under clinical development by Duality Biologics (Shanghai) and curren...
DB-1310 is under clinical development by Duality Biologics (Shanghai) and curren...
BIO’s new CEO, John Crowley, is a longtime board member — and the inspiration fo...
CVS, the nation’s largest drugstore chain, will move away from the complex formu...
Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emp...